Deutsche Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,486,467
| Closed | -$152M | – | 3887 |
|
|
2023
Q2 | $152M | Sell |
1,486,467
-8,410
| -0.6% | -$796K | 0.08% | 238 |
|
|
2023
Q1 | $136M | Buy |
1,494,877
+2,639
| +0.2% | +$155K | 0.08% | 255 |
|
|
2022
Q4 | $56.7M | Buy |
1,492,238
+472,726
| +46% | +$16.3M | 0.03% | 472 |
|
|
2022
Q3 | $25.6M | Buy |
1,019,512
+388,639
| +62% | +$10.8M | 0.02% | 693 |
|
|
2022
Q2 | $19.2M | Sell |
630,873
-1,885
| -0.3% | -$56.2K | 0.01% | 794 |
|
|
2022
Q1 | $20.7M | Sell |
632,758
-16,896
| -3% | -$501K | 0.01% | 829 |
|
|
2021
Q4 | $17.1M | Buy |
649,654
+507
| +0.1% | +$39.2K | 0.01% | 903 |
|
|
2021
Q3 | $65.3M | Buy |
649,147
+3,867
| +0.6% | +$453K | 0.03% | 504 |
|
|
2021
Q2 | $91.3M | Buy |
645,280
+37,777
| +6% | +$4.27M | 0.04% | 410 |
|
|
2021
Q1 | $60.6M | Buy |
607,503
+272,925
| +82% | +$31.8M | 0.03% | 510 |
|
|
2020
Q4 | $41.4M | Buy |
334,578
+12,877
| +4% | +$1.69M | 0.03% | 572 |
|
|
2020
Q3 | $31.3M | Buy |
321,701
+25,513
| +9% | +$3.19M | 0.02% | 577 |
|
|
2020
Q2 | $46.2M | Buy |
296,188
+35,264
| +14% | +$5.36M | 0.04% | 453 |
|
|
2020
Q1 | $37.7M | Sell |
260,924
-30,464
| -10% | -$5.88M | 0.03% | 446 |
|
|
2019
Q4 | $59.6M | Buy |
291,388
+222,083
| +320% | +$40.5M | 0.04% | 439 |
|
|
2019
Q3 | $5.56M | Buy |
69,305
+8,331
| +14% | +$707K | ﹤0.01% | 1342 |
|
|
2019
Q2 | $5.75M | Sell |
60,974
-12,837
| -17% | -$1.11M | ﹤0.01% | 1723 |
|
|
2019
Q1 | $6.3M | Sell |
73,811
-97,561
| -57% | -$8.1M | ﹤0.01% | 1697 |
|
|
2018
Q4 | $9.61M | Buy |
171,372
+47,713
| +39% | +$2.91M | 0.01% | 1332 |
|
|
2018
Q3 | $10.1M | Buy |
123,659
+85,684
| +226% | +$6.04M | 0.01% | 1626 |
|
|
2018
Q2 | $1.33M | Buy |
37,975
+19,678
| +108% | +$599K | ﹤0.01% | 3232 |
|
|
2018
Q1 | $374K | Sell |
18,297
-7,052
| -28% | -$182K | ﹤0.01% | 3882 |
|
|
2017
Q4 | $717K | Buy |
25,349
+15,069
| +147% | +$420K | ﹤0.01% | 3425 |
|
|
2017
Q3 | $318K | Sell |
10,280
-24,391
| -70% | -$734K | ﹤0.01% | 3637 |
|
|
2017
Q2 | $1.1M | Buy |
34,671
+27,926
| +414% | +$687K | ﹤0.01% | 2967 |
|
|
2017
Q1 | $152K | Buy |
6,745
+3,510
| +109% | +$86.7K | ﹤0.01% | 3732 |
|
|
2016
Q4 | $70K | Buy |
3,235
+2,300
| +246% | +$58.2K | ﹤0.01% | 4236 |
|
|
2016
Q3 | $24K | Sell |
935
-5,057
| -84% | -$100K | ﹤0.01% | 4484 |
|
|
2016
Q2 | $118K | Buy |
+5,992
| New | +$116K | ﹤0.01% | 4026 |
|
Other funds holding RETA
Deutsche Bank's RETA Position: Q3 2023 in Review
Deutsche Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,486,467 shares — an estimated $152M sold.
Deutsche Bank first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $152M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Deutsche Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Deutsche Bank sold 1,486,467 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $152M.
- Deutsche Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- Deutsche Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $152M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Deutsche Bank's 13F filing for Q3 2023, filed 9 Nov 2023.